Evidence map›Paper›PMID 37892432›Full record

ReviewNutrients2023

Ketogenic Diet and Breast Cancer: Recent Findings and Therapeutic Approaches.

Alfio Giuseppe Urzì, Emanuela Tropea, Giuseppe Gattuso, Graziana Spoto, Gabriella Marsala, Daniela Calina, Massimo Libra, Luca Falzone

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Alfio Giuseppe UrzìDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0009-0004-1935-7058
Emanuela TropeaDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Giuseppe GattusoDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-5931-2648
Graziana SpotoDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Gabriella MarsalaDipartimento del Farmaco, U.O.C. di Farmaceutica Convenzionata, 95100 Catania, Italy.
Daniela CalinaDepartment of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0002-1523-9116
Massimo LibraDepartment of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-7232-7737
Luca FalzoneEpidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy.ORCID 0000-0001-7349-6826
University of Catania · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITUniversity of Medicine and Pharmacy of Craiova · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC), a complex disease with several influencing factors, is significantly impacted by dietary habits. The ketogenic diet (KD), characterized by high fat and low carbohydrate intake, has gained attention as a potential therapeutic approach, but its effects on BC remain unclear. This review seeks to summarize the current knowledge on the principles of the KD, its metabolic influence on BC cells, and the findings of recent clinical trials, in order to elucidate the potential therapeutic role of the KD in BC management. For these purposes, a comprehensive literature review was conducted selecting preclinical and clinical studies that investigate the relationship between the KD and BC. The selection criteria prioritized studies exploring the KD's metabolic effects on BC cells and current clinical trials involving the KD in BC management. The reviewed studies provide a diverse range of findings, with some suggesting potential benefits of the KD in inhibiting tumor growth and improving treatment response. However, robust clinical trials providing clear evidence of the KD's efficacy as a standalone therapeutic approach in BC are still lacking. There are also significant concerns regarding the safety and long-term effects of sustained ketosis in cancer patients. The therapeutic potential of the KD in BC remains an area of active research and debate. While preliminary findings are promising, definitive conclusions are hindered by inconsistent results and limited human trial data. Future research, specifically well-structured, large-scale clinical trials, is necessary to provide a comprehensive understanding of the role of the KD in BC treatment. Until then, caution should be exercised in its application, and patients should continue prioritizing evidence-based, standard-of-care treatments.

Indexed as

Breast NeoplasmsDiet, KetogenicFemaleHumansbreast cancerglycemic loadintegrated treatmentsketogenesisketogenic dietproteins

Identifiers

PMID37892432
PMCPMC10609494
OpenAlexW4387614725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.